APM
ONC

Avidity Partners Management’s BeOne Medicines Ltd ONC Stock Holding History

Avidity Partners Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-132,000
Closed -$17.8M – 107
2022
Q3 		$17.8M Buy
+132,000
New +$22.7M 0.36% 55

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avidity Partners Management's ONC Position: Q4 2022 in Review

Avidity Partners Management sold out of BeOne Medicines Ltd (ONC) in Q4 2022, closing a stake of 132,000 shares — an estimated $17.8M sold.

Avidity Partners Management first reported a position in ONC in Q3 2022 and held it in 1 quarter. The position peaked at $17.8M in Q3 2022. 213 funds tracked by Wall St. Rank hold ONC as of Q4 2022.

  • Avidity Partners Management reported no remaining BeOne Medicines Ltd position as of Q4 2022 after selling out during the quarter.
  • Avidity Partners Management sold 132,000 BeOne Medicines Ltd shares in Q4 2022, an estimated $17.8M.
  • Avidity Partners Management first reported a position in BeOne Medicines Ltd in Q3 2022 and held it in 1 quarter.
  • Avidity Partners Management's BeOne Medicines Ltd position peaked at $17.8M in Q3 2022.
  • 213 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.